Utility of Measurable Residual Disease for Predicting Treatment Outcomes With BCR- and BCL2-Targeted Therapies in Patients With CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL
Leukemia and Lymphoma 2022 Aug 19;[EPub Ahead of Print], WG Wierda, TJ Kipps, O Al-Sawaf, B Chyla, JML Biondo, Y Mun, Y Jiang, JF SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.